Veterinary Intravenous Solutions Market Size, Share & Trends Report

Veterinary Intravenous Solutions Market (2025 - 2030) Size, Share & Trends Analysis Report By Product, By Animal Type (Companion Animals, Production Animals), By Indication, By End Use, By Region, And Segment Forecasts

Market Segmentation

Veterinary Intravenous (IV) Solutions Product Outlook (Revenue, USD Million, 2018 - 2030)
- Isotonic crystalloids
- Synthetic colloids
- Blood products
- Dextrose solutions
- Parenteral nutrition
Veterinary Intravenous (IV) Solutions Indication Outlook (Revenue, USD Million, 2018 - 2030)
- Diabetic Ketoacidosis
- Pancreatitis
- Anthrax
- Chronic Kidney Disease
- Others
Veterinary Intravenous (IV) Solutions Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
- Companion Animals
- Production Animals
Veterinary Intravenous (IV) Solutions End Use Outlook (Revenue, USD Million, 2018 - 2030)
- Veterinary Hospitals
- Research Institutes
- Others
Veterinary Intravenous (IV) Solutions Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - Product Outlook (Revenue, USD Million, 2018 - 2030)
    - Isotonic crystalloids
    - Synthetic colloids
    - Blood products
    - Dextrose solutions
    - Parenteral nutrition
  - Indication Outlook (Revenue, USD Million, 2018 - 2030)
    - Diabetic Ketoacidosis
    - Pancreatitis
    - Anthrax
    - Chronic Kidney Disease
    - Others
  - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Production Animals
    - Companion Animals
  - End Use Outlook (Revenue, USD Million, 2018 - 2030)
    - Veterinary Hospitals
    - Research Institutes
    - Others
  - U.S.
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others
  - Canada
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others
  - Mexico
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others
- Europe
  - Product Outlook (Revenue, USD Million, 2018 - 2030)
    - Isotonic crystalloids
    - Synthetic colloids
    - Blood products
    - Dextrose solutions
    - Parenteral nutrition
  - Indication Outlook (Revenue, USD Million, 2018 - 2030)
    - Diabetic Ketoacidosis
    - Pancreatitis
    - Anthrax
    - Chronic Kidney Disease
    - Others
  - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Production Animals
    - Companion Animals
  - End Use Outlook (Revenue, USD Million, 2018 - 2030)
    - Veterinary Hospitals
    - Research Institutes
    - Others
  - UK
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others
  - Germany
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others
  - France
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others
  - Italy
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others
  - Spain
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others
  - Denmark
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others
  - Sweden
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others
  - Norway
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others
- Asia Pacific
  - Product Outlook (Revenue, USD Million, 2018 - 2030)
    - Isotonic crystalloids
    - Synthetic colloids
    - Blood products
    - Dextrose solutions
    - Parenteral nutrition
  - Indication Outlook (Revenue, USD Million, 2018 - 2030)
    - Diabetic Ketoacidosis
    - Pancreatitis
    - Anthrax
    - Chronic Kidney Disease
    - Others
  - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Production Animals
    - Companion Animals
  - End Use Outlook (Revenue, USD Million, 2018 - 2030)
    - Veterinary Hospitals
    - Research Institutes
    - Others
  - Japan
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others
  - India
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others
  - China
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others
  - South Korea
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others
  - Australia
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others
  - Thailand
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others
- Latin America
  - Product Outlook (Revenue, USD Million, 2018 - 2030)
    - Isotonic crystalloids
    - Synthetic colloids
    - Blood products
    - Dextrose solutions
    - Parenteral nutrition
  - Indication Outlook (Revenue, USD Million, 2018 - 2030)
    - Diabetic Ketoacidosis
    - Pancreatitis
    - Anthrax
    - Chronic Kidney Disease
    - Others
  - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Production Animals
    - Companion Animals
  - End Use Outlook (Revenue, USD Million, 2018 - 2030)
    - Veterinary Hospitals
    - Research Institutes
    - Others
  - Brazil
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others
  - Argentina
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others
- Middle East and Africa (MEA)
  - Product Outlook (Revenue, USD Million, 2018 - 2030)
    - Isotonic crystalloids
    - Synthetic colloids
    - Blood products
    - Dextrose solutions
    - Parenteral nutrition
  - Indication Outlook (Revenue, USD Million, 2018 - 2030)
    - Diabetic Ketoacidosis
    - Pancreatitis
    - Anthrax
    - Chronic Kidney Disease
    - Others
  - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Production Animals
    - Companion Animals
  - End Use Outlook (Revenue, USD Million, 2018 - 2030)
    - Veterinary Hospitals
    - Research Institutes
    - Others
  - South Africa
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others
  - Saudi Arabia
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others
  - UAE
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others
  - Kuwait
    - Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Isotonic crystalloids
      - Synthetic colloids
      - Blood products
      - Dextrose solutions
      - Parenteral nutrition
    - Indication Outlook (Revenue, USD Million, 2018 - 2030)
      - Diabetic Ketoacidosis
      - Pancreatitis
      - Anthrax
      - Chronic Kidney Disease
      - Others
    - Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Production Animals
      - Companion Animals
    - End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Research Institutes
      - Others

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments